Treatment News : Higher Mortality Risk in People With HIV-Related Inflammation

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » June 2010

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


June 28, 2010

Higher Mortality Risk in People With HIV-Related Inflammation

A new study suggests that people with HIV who have high blood levels of two inflammatory proteins—fibrinogen and C-reactive protein (CRP)—might have an increased risk of premature death. The study, published online June 25 in the Journal of Acquired Immune Deficiency Syndromes, found that the increased mortality risk was present even in people with high CD4 counts.

Researchers have previously found that people with HIV—including those on antiretroviral (ARV) thereapy—might be at a three-fold higher risk of premature death than their HIV-negative counterparts, even after controlling for traditional health risk factors. The most likely culprit for the increased disease and death risk, say researchers, is a process known as inflammation. Inflammation is a natural—and usually desirable—immune response to infection and cancerous cells. Chronic inflammation, however, has been strongly associated with cardiovascular disease, liver disease and diabetes.

To determine the effect of two inflammatory proteins on survival, Phyllis Tien, MD, from the University of California in San Francisco, and her colleagues examined frozen blood samples taken from people with HIV who had participated in the Fat Redistribution and Metabolic Change in HIV Infection (FRAM) study between 2000 and 2002. In all, Tien’s group was able to test samples from 922 people and link them with health outcomes over a five-year period. The majority of those in the study were on ARV treatment.

Tien and her colleagues found that inflammation was relatively common, with roughly one third of the study participants having high levels of at least one of two inflammatory proteins: fibrinogen and C-reactive protein (CRP). This was true even in people with CD4 counts over 500. Generally, high levels of either protein were associated with older age, higher viral loads and lower CD4 cell counts.

Tien’s group also found that high levels of fibrinogen and CRP were associated with higher mortality. People with the highest blood levels of fibrinogen were almost two and a half times as likely to die within five years as people with the lowest fibronogen levels. People with the highest CRP levels were also more than twice as likely to die during the follow-up period than people with the lowest levels. There was an increased risk of death even in people with CD4 counts over 500, though the increase was smaller than in those with lower CD4 counts.

It should be noted that the overall death rates were relatively low in people who had both low fibrinogen and low CRP levels—five percent over five years—especially given that the study was conducted nearly a decade ago. The authors did not provide data on the mortality rates broken out by CD4 count, though numerous studies have documented that people with very high CD4 counts are at particularly low risk of death over a five-year period.

Nevertheless, the authors state that the connection they found between inflammation and increased mortality is worrisome. They note that a recent study found that starting ARV therapy when CD4 counts are above 500 did increase survival, and other studies have shown significant (though not complete) reductions in inflammation after ARVs are initiated. Nevertheless, Tien and her colleagues suggest that studies of other medications that can lower inflammation are warranted. “Investigation is needed to determine whether interventions to reduce fibrinogen and CRP levels might decrease mortality risk in HIV-infected individuals,” they conclude.

Search: Fibrinogen, C-reactive protein, CRP, Phyllis Tien, inflammation, death, mortality, liver

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Has a pet helped you deal with your HIV?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.